Marea Therapeutics Welcomes Ian Clements Aa New CFO

Marea Therapeutics, a pioneering biotech company advancing innovative treatments for cardiometabolic conditions through cutting-edge genetic research, has announced the appointment of Ian Clements, Ph.D., as their new Chief Financial Officer.

Josh Lehrer, M.D., M.Phil., FACC, chief executive officer of Marea, “Marea is entering a period of growth and rapid advancement to clinical milestones following our recent launch, completion of our Series B financing, and with our lead program, MAR001, advancing in Phase 2 clinical development. It is a pleasure to welcome Ian during this important time. We are confident that his financial expertise and business acumen will help propel our efforts as we aim to accelerate a new generation of medicines that treat key unaddressed drivers of cardiometabolic disease.”

Dr. Clements brings a wealth of experience in biopharmaceutical business leadership to Marea. Before joining Marea, he was the Chief Financial Officer at Mirum Pharmaceuticals, guiding the company from its inception through its successful IPO. In this role, he managed a range of functions including financial reporting, planning, accounting, internal controls, corporate affairs, investor relations, legal, facilities, and IT.

Before his time at Mirum, Dr. Clements was Vice President of Investor Relations at Dermira, Inc., and earlier held the same title at Tobira. His career also includes a role as Head of Investor Relations and Corporate Communications at Avanir Pharmaceuticals, as well as leadership positions at Sequenom and The Trout Group, where he oversaw west coast operations for life sciences investor relations. Dr. Clements holds a Ph.D. in Chemistry from the University of Manchester, an M.B.A. from the Open University in the UK, and a B.Sc. in Chemistry from Staffordshire University.

Dr. Clements, “Marea is a compelling company that holds remarkable promise and is well-positioned to transform the way cardiometabolic diseases are treated. I am enthusiastic about joining this skilled team, and am impressed by their scientific rigor, their passion, and their patient focus. I look forward to working with the team to build on the company’s strong foundation and to help realize MAR001’s potential in cardiometabolic diseases and delivering value to patients and shareholders.”